Flightpath

3 known investors

Flightpath Biosciences develops Targeted Bacterial Deletion, a platform that selectively removes harmful gram-negative bacteria while sparing the surrounding microbiome to interrupt infection-driven disease. Its pipeline targets bacterial drivers across oral and gastrointestinal diseases, infection-associated cancers, and women's health conditions.